Amicus Therapeutics (NASDAQ:FOLD) Releases FY 2021 Earnings Guidance

Amicus Therapeutics (NASDAQ:FOLD) issued an update on its FY 2021 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of – for the period. The company issued revenue guidance of $300 million-$315 million, compared to the consensus revenue estimate of $312.64 million.

Shares of NASDAQ:FOLD traded up $0.21 during trading on Tuesday, reaching $9.60. 1,853,760 shares of the company’s stock traded hands, compared to its average volume of 3,678,528. Amicus Therapeutics has a fifty-two week low of $8.83 and a fifty-two week high of $25.39. The company has a quick ratio of 5.10, a current ratio of 5.24 and a debt-to-equity ratio of 1.21. The firm has a market cap of $2.55 billion, a PE ratio of -8.36 and a beta of 1.57. The company has a 50-day simple moving average of $9.79 and a 200-day simple moving average of $16.79.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Sunday, May 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.24) by ($0.01). Amicus Therapeutics had a negative net margin of 120.18% and a negative return on equity of 73.81%. On average, equities research analysts forecast that Amicus Therapeutics will post -1.03 EPS for the current year.

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald raised shares of Amicus Therapeutics from a neutral rating to an overweight rating in a research note on Monday, April 19th. Citigroup decreased their price target on shares of Amicus Therapeutics from $27.00 to $16.00 in a research note on Friday, February 12th. JPMorgan Chase & Co. lowered shares of Amicus Therapeutics from an overweight rating to a neutral rating and set a $19.00 price target on the stock. in a research note on Friday, February 12th. Robert W. Baird reaffirmed a buy rating on shares of Amicus Therapeutics in a research note on Wednesday, March 3rd. Finally, Stifel Nicolaus assumed coverage on shares of Amicus Therapeutics in a research note on Monday, March 8th. They issued a hold rating and a $13.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company. Amicus Therapeutics presently has an average rating of Hold and an average target price of $20.31.

In other news, Director Margaret G. Mcglynn sold 10,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, May 3rd. The shares were sold at an average price of $10.27, for a total transaction of $102,700.00. Following the sale, the director now owns 37,919 shares of the company’s stock, valued at approximately $389,428.13. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO John F. Crowley sold 22,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, March 15th. The shares were sold at an average price of $10.77, for a total transaction of $236,940.00. Following the sale, the chief executive officer now directly owns 858,706 shares in the company, valued at approximately $9,248,263.62. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 105,393 shares of company stock worth $1,083,109. Corporate insiders own 2.50% of the company’s stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates.

Recommended Story: What is the Dividend Aristocrat Index?

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.